Why Most Peptide Drugs Can't Be Taken as a Pill: Oral Bioavailability and the Enzyme-Degradation Problem

Most peptide-based medications, from insulin to semaglutide to growth-hormone therapies, are injected rather than swallowed. That's not a historical accident or a manufacturing preference; it reflects a specific, well-understood biochemical obstacle called oral bioavailability, and it's a big part of why an oral GLP-1 pill was considered a significant engineering achievement rather than an obvious next step.

What Bioavailability Means

Bioavailability refers to the proportion of a dose that actually reaches the bloodstream in an active form. A drug can be perfectly effective when delivered directly into the blood but nearly useless when swallowed, if it doesn't survive the trip through the digestive system intact.

Why Peptides Struggle With That Trip

Peptides are chains of amino acids, which is exactly what the digestive system is built to break down. The stomach's acidic environment and enzymes like pepsin, along with pancreatic and intestinal enzymes further down the digestive tract, exist specifically to cut proteins and peptides into individual amino acids for absorption as nutrients. A peptide drug swallowed as a pill faces that same enzymatic machinery, which doesn't distinguish between a peptide that's food and a peptide that's medicine, and will often break it down before it reaches the small intestine wall. Even a peptide that survives digestion intact still has to cross the intestinal lining into the bloodstream, and peptides are generally too large and too water-soluble to pass through that barrier efficiently, compounding the problem.

How Oral Semaglutide Gets Around This

Oral semaglutide (marketed as Rybelsus, and distinct from the once-weekly injectable version) solves part of this problem using an absorption enhancer called SNAC, which is co-formulated in the same tablet. SNAC works by locally and temporarily raising the pH around the tablet in the stomach, which protects the semaglutide from being broken down by pepsin, and by temporarily increasing permeability of the stomach lining, allowing a small fraction of the dose to be absorbed before the protective window closes. The result is still a very inefficient process. Oral semaglutide's bioavailability is roughly 1%, meaning the oral tablet dose has to be dramatically larger than the injectable dose to deliver a comparable amount of active drug, and prescribing information for it specifies it must be taken on an empty stomach with a small amount of water, with no other food, drink, or oral medication for 30 minutes afterward, specifically to avoid diluting or displacing the SNAC-created absorption window.

Other Approaches in Development

Newer oral candidates in development, including small-molecule GLP-1 agonists like orforglipron, take a different approach entirely: rather than trying to improve peptide absorption, they're not peptides at all, but small organic molecules designed from the start to survive digestion and cross the gut lining the way conventional pills do, which is part of why orforglipron doesn't require the same empty-stomach, no-food restrictions that oral semaglutide does.

The Bottom Line

The injection requirement for most peptide drugs isn't a design shortcoming; it's a direct consequence of peptide chemistry meeting digestive-system chemistry. Getting around it requires either an absorption-enhancing workaround, as with oral semaglutide, or redesigning the drug as a non-peptide molecule altogether, as with newer oral candidates, and each approach comes with its own tradeoffs in bioavailability, dosing complexity, and side effects.